

The key to gene therapy success


Reliable testing of pre-existing anti-AAV immunogenicity

AAV vectors are vital for gene therapy, enabling the delivery of genetic material with precision. However, pre-existing immunity can neutralize them, hindering research. Pre-testing overcomes this barrier, ensuring reliable data and faster progress.

The prevalence of pre-existing immunity


Pre-existing AAV immunity is a significant obstacle for gene therapy research.

Antibodies, present in much of the population neutralize therapeutic vectors, complicating both preclinical and clinical research.



These variations emphasize the need for robust pre-testing to prevent invalid models, wasted resources, and unreliable data, ultimately ensuring research accuracy and accelerating therapeutic progress.

How AAV immunogenicity testing drives insights



Pre-testing detects immune barriers early, guiding model selection and strategy refinement. Identifying antibodies across serotypes reduces trial risks, accelerating therapeutic progress.

The impact of undetected immunity

Failing to test for anti-AAV antibodies undermines research reliability, delays therapies and increases costs.



Each delay extends clinical trial timelines, increases costs, and slows patient access to life-changing treatments.

Set the foundation for success



Robust pre-testing ensures reliable gene therapy research by enhancing accuracy, reducing variability and guiding capsid design. Addressing immunity early minimizes risks, optimizes resources, and accelerates therapeutic progress.

Pre-test with confidence. Explore tools to accelerate breakthroughs.

About Gyrolab®

At Gyros Protein Technologies, we offer innovative automated systems for accelerating immunoassays and peptide synthesis. Our Gyrolab platform delivers reliable immunoassay results - up to four times faster than traditional ELISA - while our advanced peptide synthesis technologies provide high-quality peptides essential for research and development. Trusted by laboratories worldwide, we enable you from discovery through development to manufacture, driving progress in biotherapeutic drugs.

References

- ¹ <https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.999021/>
- ² https://ashpublications.org/blood/article/134/Supplement_1/3353/423771/Seroprevalence-of-Pre-Existing-Nabs-Against-AAV1-2?
- ³ <https://journals.asm.org/doi/10.1128/cvi.05107-11?>
- ⁴ <https://ashpublications.org/blood/article/140/Supplement%201/10668/487952/Global-Seroprevalence-of-Neutralizing-Antibodies?>